Caribou Biosciences, Inc. Marketable Securities (Current)
Caribou Biosciences, Inc. (CRBU) had Marketable Securities (Current) of $227.78 million as of 2022-06-30, per its 10-Q filed 2022-08-09.
Discontinued › Balance Sheet › Assets › Assets, Current › Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2022-08-09
- 2022-06-30: Marketable Securities, Current $227.78M.
- 2022-03-31: Marketable Securities, Current $206.10M.
- 2021-12-31: Marketable Securities, Current $135.41M.
- 2020-12-31: Marketable Securities, Current $0.00.
| Period end | Marketable Securities, Current |
|---|---|
| 2022-06-30 | $227.78M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $206.10M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $135.41M 10-Q · filed 2022-08-09 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |